Hemorrhagic Stroke Market Analysis, Size, Share & Growth Forecast 2026–2034

ENRICH Minimally Invasive Parafascicular ICH Evacuation Achieving 45 vs 24 Percent Functional Independence at 180 Days in Lobar Haematoma 30 to 80 mL Represents the First Surgical ICH Trial Demonstrating Functional Benefit for the Specifically Defined Patient That Broader ICH Surgical Trials Failed to Show.The ENRICH trial comparing early minimally invasive surgery using the NICO Myriad system with medical management in spontaneous ICH patients demonstrated a 9.1-point improvement in 180-day NIHSS versus 0.3 for medical management, earning the NICO Myriad system FDA clearance and establishing the first randomised evidence for surgical ICH treatment in appropriately selected patients. The parafascicular surgical corridor minimises cortical traversal injury by using a tubular retraction system through a 1-2 cm craniotomy rather than the wide craniotomy required for craniotomy and clot evacuation that failed to demonstrate benefit in prior randomised trials. Patient selection for ENRICH-eligible surgery requires lobar or anterior basal ganglia haematoma volume 15-80 mL presenting within 24 hours, which identifies approximately 20-30% of spontaneous ICH patients who meet anatomical and timing criteria for the procedure.

INTERACT-2 and ATACH-2 Intensive Systolic BP Reduction Below 140 mmHg Within 1 Hour of ED Arrival as Acute ICH Management Targeting the 30 to 40 Percent of Patients With Haematoma Expansion Has Established the Blood Pressure Target That Acute Haemostatic Control Requires.The TICH-2 trial of tranexamic acid in 2,325 acute ICH patients demonstrated significant reduction in 24-hour haematoma expansion but no significant difference in 90-day modified Rankin Scale score despite achieving its haemostasis pharmacodynamic endpoint, illustrating the challenge that haematoma expansion reduction may be necessary but insufficient for functional outcome improvement in a condition where the neurological damage from initial bleeding and surrounding oedema is substantial regardless of expansion prevention. The STOP-MSU prehospital tranexamic acid trial in ambulance-treated ICH is testing whether earlier administration before hospital arrival achieves the haemostasis benefit at a time point where preventing expansion has greater functional relevance. The SPOTLIGHT trial combining tranexamic acid with early intensive blood pressure reduction is investigating whether dual haemostatic and haemodynamic intervention produces the functional benefit that each intervention alone has failed to establish.

Nimodipine SAH Delayed Cerebral Ischaemia Prevention Without Reducing Angiographic Vasospasm Frequency Demonstrates the Clinical Dissociation Between Vasospasm and DCI That the Calcium Channel Blocker Addresses Through Mechanisms Beyond Vasodilation That Explain Its Efficacy.AstraZeneca's Andexxa demonstrated haemostatic efficacy in 82% of anti-factor Xa anticoagulated patients with major bleeding including ICH in ANNEXA-4, earning FDA approval for reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding. The 10-18% thrombotic event rate within 30 days in ANNEXA-4 reflects both the underlying patient vascular disease that precipitated anticoagulation and potentially the excess thrombin generation from supratherapeutic factor Xa restoration, creating a clinical benefit-risk assessment that guideline bodies have framed as appropriate in major haemorrhage requiring immediate reversal. The ANNEXA-I trial in DOAC-associated ICH demonstrated superior haemostatic efficacy and non-inferior 90-day outcomes versus usual care, establishing andexanet alfa as the preferred reversal agent for factor Xa anticoagulant-associated ICH in centres where the USD 30,000+ cost per dose is supported by specialty pharmacy infrastructure.

For related market intelligence, see the Stroke Market.